The impact of the 21-gene recurrence score assay on decision making about adjuvant chemotherapy in early-stage estrogen-receptor-positive breast cancer in an oncology practice with a unified treatment policy

Annals of Oncology

Volumn 22, Issue 11, 2011, Pages 2381-2386

  Geffen, D B ^a   Abu Ghanem, S ^a   Sion Vardy, N ^a   Braunstein, R ^b   Tokar, M ^a   Ariad, S ^a   Delgado, B ^a   Bayme, M ^a   Koretz, M ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b Independent Consultant   (Israel)

Author keywords

Adjuvant chemotherapy; Breast cancer; Decision making; Recurrence score

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PACLITAXEL; PROGESTERONE RECEPTOR; RNA;

21 GENE RECURRENCE SCORE ASSAY; ADJUVANT ONLINE SCORE; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL PRACTICE; COMPUTER PROGRAM; CONTROLLED STUDY; FEMALE; GENETIC ANALYSIS; HEALTH CARE POLICY; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RNA ANALYSIS; SCORING SYSTEM;

EID: 80051543871     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq769     Document Type: Article

References (25)

1. Sotirou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009; 360: 790-800.
2. Habel LA, Shak S, Jacobs MK et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 2006; 8: R25.
3. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node negative breast cancer. N Engl J Med 2004; 351: 2817-2826.
4. Paik S, Tang G, Shak S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24: 3726-3734.
5. Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008; 26: 721-728.
6. Albain KS, Barlow WE, Shak S et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy; a retrospective analysis of a randomized trial. Lancet Oncol 2010; 11: 55-65.
7. Dowsett M, Cuzick J, Wale C et al. Prediction of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a trans ATAC study. J Clin Oncol 2010; 28: 1829-1834.
8. Palmer G, Vaughn J, Schneider DJ, Haack B. The distribution of recurrence scores in Europe and Middle East (EME) compared with the US. Eur J Cancer Suppl 2009; 7: 148 (Abstr).
9. Lo SS, Mumby PB, Norton J et al. Prospective multicenter study of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 2010; 28: 1671-1676.
10. Henry LR, Stojadinovic A, Swain SM et al. The influence of a gene expression profile on breast cancer decisions. J Surg Oncol 2009; 99: 319-323.
11. Asad J, Jacobson AF, Estabrook A et al. Does oncotype Dx recurrence score affect the management of patients with early-stage breast cancer? Am J Surg 2008; 196: 527-529.
12. Oratz R, Paul D, Cohn AL, Sedlacek SM. Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer. J Oncol Pract 2007; 3: 182-186.
13. Oratz R, Chao C, Skrypczak S et al. Effect of 21-gene recurrence score results on treatment recommendations in patients with lymph-node positive, estrogen receptor-positive breast cancer. Cancer Res 2009; 69(24 Suppl): (Abstr 2031).
14. Klang SH, Hammerman A, Leibermann N et al. Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization. Value Health 2010; 13: 381-387.
15. Adjuvant, Inc. Adjuvant! Online, Decision making tools for health care professionals. www.adjuvantonline.com (22 August 2010, date last accessed).
16. Albain K, Barlow W, Shak S et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ER-positive breast cancer. Breast Cancer Res Treat 2007; 106(Suppl): (Abstr 10).
17. Toi M, Yamanaka T, Masuda N et al. Clinical significance of the 21-gene signature (oncotype DX) in the hormone receptor-positive early stage primary breast cancer in the Japanese population. Cancer 2010; 116: 3112-3118.
18. Olivotto IA, Bajdik CD, Ravdin P et al. Population-based validation of the prognostic model Adjuvant! for early breast cancer. J Clin Oncol 2005; 23: 2716-2725.
19. Wolf I, Ben-Baruch N, Shapira-Frommer R et al. Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients. Cancer 2008; 112: 731-736.
20. Goldstein LJ, Gray R, Badve S et al. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 2008; 26: 4063-4071.
21. Bueno-de-Mesquita JM, Nuyten DSA, Wessling J et al. The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment. Ann Oncol 2010; 21: 40-47.
22. Bueno-deMesquita JM, van Harten WH, van't Veer LJ et al. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol 2007; 8: 1079-1087.
23. Cardoso F, Van't Veer L, Rutgers E et al. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 2008; 26: 729-735.
24. National Comprehensive Cancer Network, NCCN Clinical Practice Guidelines in Oncology, Breast Cancer. http://www.nccn.org (22 August 2010 date last accessed).
25. Goldhirsch A, Ingle JN, Gelber RD et al. Thresholds for therapies: highlights of the St. Gallen International expert consensus of early breast cancer 2009. Ann Oncol 2009; 20: 1319-1329.